Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
206 Leser
Artikel bewerten:
(1)

endpoint Clinical: endpoint and Berlinger Collaborate to Provide Complete Visibility of the Historical Temperature Journey of an IMP

Fully integrated solution: Turn a 25-day manual temperature-monitoring data evaluation into instant decision making

SAN FRANCISCO and SWITZERLAND, Oct. 6, 2021 /PRNewswire/ -- endpoint Clinical, the leader in global interactive response technology (IRT) for clinical trials, and Berlinger & Co. AG, specializing in the production of innovative and customized solutions for monitoring temperature-sensitive goods in the pharmaceutical and medical industry, have announced their partnership to provide complete end to end visibility of the entire temperature history of an Investigational Medicinal Product (IMP).

endpoint clinical logo

"Over the last several years, the cold chain logistics market for clinical trials has shown a growth of about 10%. This is largely related to the increasing number of biologicals and monoclonal antibodies that are under study. Therefore, cold chain failure in clinical trials has an increasing impact," says Dr. Harald van Weeren, Segment Manager Clinical Trials at Berlinger.

Our organizations understand the risks of managing temperature-controlled IMP, and therefore, we focused on designing a solution to help reduce risk and eliminate the core issues. Such problems include limited transparency and missing information, the lack of immediate centralized visibility, time-consuming excursion management and slow decision making, time-consuming data consolidation for audits, wastage of drugs, and patient rescheduling or lost.

Through this partnership, endpoint and Berlinger can provide Sponsors with a fully integrated solution, taking a 25-day manual temperature-monitoring data evaluation and turning it into instant decision making. This drastically reduces costs up to 7-digit figures and improves patient safety, allowing for fast decision-making through complete visibility of the temperature history.

Sponsors and sites will reap immediate benefits through this sophisticated technology integration in a variety of areas:

  • Education: Less instruction needed for the site users
  • Handling: A reduction in admin time, manual handling, and associated risks
  • Excursion Management: Reduce the risk for dispensing drugs affected by a temperature deviation
  • Patient: Reduce failed patient visits and increase patient safety
  • Audit: All of the temperature data available in one system for easy preparation
  • Drugs: Reduce waste of trial products

"Patient safety has always been a high priority for endpoint. As cold chain logistics become increasingly important due to the ever-growing number of studies that work with biologics, we understand how vital it is to maintain the chain of custody. This ensures that IMP does not go outside of agreed temperature ranges for that product. We are happy to be partnering with Berlinger on an integration providing a seamless solution for both the sponsor and site," says Jeff Rubesin, Senior Director, Product Strategy at endpoint Clinical.

About endpoint
endpoint is an interactive response technology (IRT) systems and solutions provider that supports the life sciences industry. For the past decade, their customer-obsessed team of professionals has been continuously evolving their suite of technologies to help Sponsors achieve clinical trial success. Their dynamic IRT solution, PULSE, for patient randomization and management, site management, and drug supply management and leading-edge clinical supplies management tool, DRIVE, has proven to maximize the supply chain and minimize operational costs, and ensure timely and accurate patient dosing. endpoint is headquartered in San Francisco, California, with offices across the US, EU, and Asia. www.endpointclinical.com

About Berlinger
Berlinger is a traditional and independent Swiss and family-owned company that is specialized in the production of innovative and customized solutions for monitoring temperature-sensitive goods in the pharmaceutical and medical industry as well as for doping control equipment to ensure safe transportation and storage of urine and blood samples in the sports industry.

Established in 1865 as a weaving manufacturer, Berlinger has developed its business over the years and has become a world-leading manufacturer of Doping Control Equipment and is among the top three leaders in the market of temperature monitoring solutions.

Visit https://www.berlinger.com/usa/ to learn more.

Contacts:
Monica Holt
Marketing Communications Manager
endpoint Clinical
e: mholt@endpointclinical.com

Barbara Hoefelmayr
Marketing Manager
Berlinger
+41 71 982 86 02
e: barbara.hoefelmayr@berlinger.com

Logo - https://mma.prnewswire.com/media/1654012/endpoint_Logo.jpg

© 2021 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.